BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 9092286)

  • 1. Organ-sparing treatment of bladder cancer: an innovative approach.
    Kaufman DS; Shipley WU
    Am Fam Physician; 1997 Mar; 55(4):1257-62. PubMed ID: 9092286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer.
    Colvett KT; Althausen AF; Bassil B; Heney NM; McGovern FV; Young HH; Kaufman DS; Zietman AL; Shipley WU
    J Surg Oncol; 1996 Nov; 63(3):201-8. PubMed ID: 8944067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
    Mak RH; Zietman AL; Heney NM; Kaufman DS; Shipley WU
    BJU Int; 2008 Nov; 102(9 Pt B):1345-53. PubMed ID: 19035903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
    Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.
    Shipley WU; Kaufman DS; Heney NM; Althausen AF; Zietman AL
    J Urol; 1999 Aug; 162(2):445-50; discussion 450-1. PubMed ID: 10411054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bladder cancer: realities and perspectives].
    Chrétien Y; Oudard S; Durdux C
    Bull Cancer; 2003 Jan; 90(1):61-7. PubMed ID: 12609806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bladder-sparing therapy for muscle-infiltrating bladder cancer.
    Pansadoro V; Emiliozzi P
    Nat Clin Pract Urol; 2008 Jul; 5(7):368-75. PubMed ID: 18560383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organ preservation for muscle-invasive bladder cancer by transurethral resection.
    Leibovici D; Kassouf W; Pisters LL; Pettaway CA; Wu X; Dinney CP; Grossman HB
    Urology; 2007 Sep; 70(3):473-6. PubMed ID: 17905099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgery.
    Merseburger AS; Kuczyk MA
    Curr Opin Urol; 2007 Sep; 17(5):358-62. PubMed ID: 17762631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined therapy for patients with invasive bladder cancer].
    Startsev VIu; Karelin MI
    Vopr Onkol; 2003; 49(2):235-8. PubMed ID: 12785212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodality therapy for the treatment of muscle-invasive bladder cancer.
    Thurman SA; DeWeese TL
    Semin Urol Oncol; 2000 Nov; 18(4):313-22. PubMed ID: 11101096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
    Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
    Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organ-sparing strategies in the management of invasive bladder cancer.
    Yafi FA; Cury FL; Kassouf W
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1765-75. PubMed ID: 19954288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Herr HW
    Eur Urol; 2009 Apr; 55(4):920-1. PubMed ID: 18722043
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Witjes JA
    Eur Urol; 2009 Apr; 55(4):919. PubMed ID: 18722044
    [No Abstract]   [Full Text] [Related]  

  • 17. Multimodality bladder preservation therapy for muscle-invasive bladder tumors.
    Fernando SA; Sandler HM
    Semin Oncol; 2007 Apr; 34(2):129-34. PubMed ID: 17382796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of radiation therapy and combined-modality treatment for bladder cancer.
    Rödel C
    Strahlenther Onkol; 2004 Nov; 180(11):701-9. PubMed ID: 15549188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical bladder preserving strategies in the treatment of muscle-invasive bladder cancer.
    Kuczyk M; Machtens S; Bokemeyer C; Kollmannsberger C; Hartmann J; Kondoh M; Merseburger A; Jonas U
    World J Urol; 2002 Aug; 20(3):183-9. PubMed ID: 12196902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.